ReleaseWire Connect

Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs market. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market has nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions. Darbepoetin alfa is a fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.

Turbocharger Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $19 billion by 2022, registering a CAGR of 11.1% during the period 2016-2022. In 2015, Europe dominated the world turbocharger market and commanded more than 40% share of the overall turbocharger market revenue, followed by Asia-Pacific and North America. The European turbocharger market growth is mainly driven by factors such as stringent government regulations related to emission & fuel-efficiency, and increase in popularity among key automakers for downsizing the engine & increasing efficiency.

Indian Modular Switch Market Report, published by Allied Market Research, forecasts that themarket is expected to garner $1,595.0 million by 2022, registering a CAGR of 22% during the period 2016-2022. Among different sales channels, the sales through intermediary is expected to dominate the market throughout the analysis period. Further, among regions, the West India dominated the market in terms of market share and accounted for around 32% share of the overall Indian modular switch market in 2015.

Increase in adoption of combination therapies instead of traditional cytotoxic therapies is a major factor that contributes to the market growth. The combinational therapies which include targeted therapy and immunotherapy (Biologic therapy), is expected to witness ~10% surge in its market share collectively by 2020.

Flip Chip Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $46 billion by 2022, registering a CAGR of 9% during the period 2016-2022. In the year 2015, Asia-Pacific dominated the global flip chip market and contributed over half of the market share owing to thriving market for semiconductors and electronic devices.

Industrial Emission Control Systems Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $21,133 million by 2022. Electrostatic precipitators (ESP) are estimated to dominate the market from 2015-2022. Asia-Pacific led the market, accounting for around 40% of the global market in 2015.

Metal Recycling Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $446,472 million, registering a CAGR of 4.5% during the period 2016 - 2022. Moreover, Asia-Pacific is expected to dominate the global market throughout the analysis period, registering a notable CAGR of 5.2%.

Global Escalators Market Report, published by Allied Market Research, forecasts that the escalators market size to reach $5,146 million by 2022, growing at a CAGR of 5.3% from 2016 to 2022. Parallel escalators segment generated the largest market share in 2015 while the others segment is expected to register highest growth rate during the forecast period. Asia-Pacific is expected to be the largest market during the forecast period.

The global CPRC therapeutics market has witnessed high growth in the past few years and would continue to grow at a consistent pace due to the high unmet clinical need associated with the disease. Large amount of drugs in pipeline, augmented patient awareness and untapped nmCRPC space would largely drive the market growth during the forecast period. On the other hand, introduction of novel treatments would be difficult as long as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require an improvement in overall survival period. Moreover, lack of differentiation in mechanism of action among the approved and novel agents along with factors such as premium pricing and uncertain reimbursement policies would hinder the market growth during the analysis period.

Inflammation is the mechanism of innate immunity, which eliminates the cause of injury. Sometimes, the body's defense system inappropriately triggers inflammation against its own cells, resulting in inflammatory autoimmune diseases. Reducing inflammation is one of the primary therapeutic strategies in acute as well as chronic diseases such as arthritis, psoriasis, and asthma. The rising incidences of autoimmune and respiratory conditions, extensive drug development pipeline, and increasing popularity of anti-inflammatory drugs with lesser side effects are the key factors driving the growth of the global anti-inflammatory therapeutics market. In addition, growing awareness about anti-inflammatory therapeutics and government initiatives, in the Asia pacific and LAMEA would further boost the market growth. However, adverse effects associated with long term consumption of drugs, namely NSAIDs and Corticosteroids would limit the market growth to a certain extent.